<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007837</url>
  </required_header>
  <id_info>
    <org_study_id>GHS-ERC: 05/05/2012</org_study_id>
    <nct_id>NCT02007837</nct_id>
  </id_info>
  <brief_title>Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial</brief_title>
  <acronym>4P</acronym>
  <official_title>Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) - a Randomised, Placebo-controlled, Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ghana Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertensive disorders of pregnancy (HDP) are with 50.000 deaths every year one of the major
      causes of maternal mortality worldwide, especially in low and middle income countries. This
      trial aims to determine whether a daily dose of combined low-dose aspirin, calcium, vitamin
      D3, folic acid and vitamin B12 in pregnancy reduces the incidence of pregnancy-induced
      hypertension in women at risk. Secondary and tertiary objectives include other maternal and
      neonatal outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of pregnancy-induced hypertension (PIH) in pregnancy</measure>
    <time_frame>up to 2 days after delivery.</time_frame>
    <description>Development of a de novo systolic blood pressure (SBP) of &gt; 140 mmHg, diastolic blood pressure (DBP) of &gt;90 mmHg, measured at least twice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal/obstetric outcomes</measure>
    <time_frame>6-16 weeks gestation, 16-24 weeks gestation, 26-36 weeks gestation, delivery and first days after</time_frame>
    <description>maternal death, preeclampsia, eclampsia, hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, hemorrhage, caesarian section, other complications during pregnancy or delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal and infant outcomes</measure>
    <time_frame>6-16 weeks gestation, 16-24 weeks gestation, 26-36 weeks gestation, delivery and first days after</time_frame>
    <description>preterm birth, Intra uterine death, stillbirth, neonatal mortality, congenital abnormality, Neonatal Intensive Care Unit (NICU) admission or pediatrician referral, birth weight, small for gestational age, apgar scores, other adverse effects. Infant outcomes: weight and height, health, occurrence of disease and general health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with (severe) adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with (severe) adverse events. Adverse events include any undesirable experience associated with the use of a medical product. Related to the product, bleeding incidences (including bruises), nausea, vomiting, will be explicitly reported.
Severe adverse events are: death, life-threatening conditions, (prolonged) hospitalization, disability and permanent damage to mother or fetus, congenital abnormality, or other important (serious) medical events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Pregnancy Induced Hypertension</condition>
  <arm_group>
    <arm_group_label>Combined aspirin and multinutrient supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5mg folic acid, cellulose filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined aspirin and multinutrient supplement</intervention_name>
    <description>Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.</description>
    <arm_group_label>Combined aspirin and multinutrient supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Daily text reminder text messages</intervention_name>
    <arm_group_label>Combined aspirin and multinutrient supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;16 weeks of gestation and over 18 years of age,

          -  Intention to have subsequent antenatal visits and delivery at the same clinic.

          -  Can receive text messages by phone or through the phone of a proxy.

          -  A moderate to high risk (&gt;20%) of developing PIH

        Exclusion Criteria:

          -  Pre-existing hypertension or hypertension before 20 weeks gestation.

          -  Likely non-compliance with the protocol in view of the treating physician

          -  Comorbidity interfering with the protocol

          -  Known contraindications to Investigational Product components
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diederick E Grobbee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Frimpong, MBbCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghana Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel K Srofenyoh, MBbCb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghana Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce L Browne, MD, MSc</last_name>
    <phone>+31649650071</phone>
    <email>J.L.Browne@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diederick E Grobbee, MD, PhD</last_name>
    <phone>+31 (0)88 755 9358</phone>
    <email>D.E.Grobbee@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>La General Hospital</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Frimpong, MBChB</last_name>
      <phone>+233244270320</phone>
      <email>patrickfrimpong@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Frimpong, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ridge Regional Hospital</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel K Srofenyoh, MBChB</last_name>
      <phone>+233208118509</phone>
      <email>emmanuelsrofenyoh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Emmanuel K Srofenyoh, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Joyce L. Browne</investigator_full_name>
    <investigator_title>MD, MSc,PhD candidate</investigator_title>
  </responsible_party>
  <keyword>pregnancy induced hypertension</keyword>
  <keyword>gestational hypertension</keyword>
  <keyword>pre-eclampsia</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>hypertensive disorders in pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

